Topline Phase III data of avatrombopag for treatment of chemotherapy-induced thrombocytopenia

Though avatrombopag increased platelet counts relative to placebo, the study did not meet the composite primary endpoint of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by four days or more.

Source:

Biospace Inc.